WuXi AppTec has announced that has acquired Pharmapace (San Diego, California), a clinical research services company with expertise in providing biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Pharmapace will become a wholly owned subsidiary of WuXi Clinical and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical’s other clinical development services.
Pharmapace, which was founded in 2013, provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing. The acquisition enables WuXi Clinical to expand its biometrics capabilities in the US and Europe. By integrating Pharmapace and WuXi Clinical biometrics teams, WuXi Clinical will be able to provide its customers with efficient and cost-effective biometrics services, the company says.
“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services,” says Edward Hu, co-CEO, WuXi AppTec. “Together, we [will be] able to shorten time-to-market of new drugs and to achieve the dream that ‘every drug can be made and every disease can be treated’,” Hu says.
By Michael Ravenscroft
Source: Chemical Week
The investment enables the steam cracker to increase the share of renewable and recycled raw materials used in its (ethylene and propylene) production. The move supports the Borealis Strategy 2030 for a circular economy. The Porvoo investment program is expected to be completed in 2025.
Murray Auchincloss, bp’s CEO, said in a statement: “As I set out in February, BP’s destination from IOC [international oil company] to IEC [integrated energy company] is unchanged – and we need to deliver as a simpler, more focused, and higher-value company.
Founded in 1972, Tecnofilm has expanded its product portfolio over the years to offer a wider range of compounds and functional polymers for various industrial applications and technical articles. The company has patented several of its products.
